Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    Study Data Find Role for Ivabradine in Treating Patients With Heart Failure Experiencing Angina: Presented at CCC - (DGDispatch)
    Migraine and cardiovascular disease: systematic review and meta-analysis - (BMJ)
    TopAbstracts in Angina Pectoris/MI 10/28/2009 - (DGNews)
    Radial Approach to PCI Associated With Less Bleeding Relative to the Femoral Approach: Presented at CCC - (DGDispatch)
    New Canadian Cholesterol-Lowering Guidelines Target Immediate-Risk Group: Presented at CCC - (DGDispatch)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
      Keys to Successful Outcomes from Anticoagulant and Antiplatelet Therapy: Addressing Medication Therapy Management Issues
      Cardiovascular Series: Guidelines for Anticoagulant and Antiplatelet Therapy in the Prevention and Treatment of Acute Coronary Syndrome: Incorporation into Clinical Practice
      Translating Evidence-Based Guidelines into Clinical Practice in the Management of Acute Coronary Syndrome
      Advancing the Standard of Care: Cardiovascular and Neurovascular Emergencies
      Anti-inflammatory and Anti-atherogenic Effects of Insulin

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        Myocardial Ischemia with Left Ventricular Outflow Obstruction
        Cardiovascular Magnetic Resonance of Myocardial Infarction After Blunt Chest Trauma: A Heartbreaking Soccer-Shot
        Spontaneous and Simultaneous Multivessel Coronary Spasm Causing Multisite Myocardial Infarction, Cardiogenic Shock, Atrioventricular Block, and Ventricular Fibrillation
        Successful Non Contrast Percutaneous Coronary Intervention for Patient with Unstable Angina and Prior Anaphylactic Reaction to Iodinated Contrast Medium
        Cardiac CT and MRI Guide Surgery in Impending Left Ventricular Rupture After Acute Myocardial Infarction

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Combined Eptifibatide/Reduced Tenecteplase Needs Further Study Before General Use In ST-Elevation Myocardial Infarction

        A DGReview of :"Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial"
        Journal of the American College of Cardiology (JACC)

        04/29/2003
        By Elda Hauschildt


        Double-bolus eptifibatide plus half-dose tenecteplase (TNK) tends to improve angiographic flow and ST-segment resolution in patients with ST-elevation myocardial infarction (STEMI).

        Researchers from the United States caution, however, that the combination is also associated with more transfusions and non-cerebral bleeding.

        Investigators from Brigham and Women's Hospital in Boston, Massachusetts, say that further study is needed before the combination therapy is recommended for general use.

        Glycoprotein IIb/IIIa inhibitors enhance thrombolysis, but the role of combined therapy in clinical practice has not been established, they explain. A total of 438 patients with STEMI of less than six hours were enrolled. Participants all received aspirin and unfractionated heparin.

        In the dose-finding section of the study, 189 patients were randomised to different combinations of double-bolus eptifibatide plus reduced-dose TNK. In the dose-confirmation section, 249 patients were randomised one to one to eptifibatide 180 microgram/kg bolus, 2 microgram/kg/min infusion and 180 microgram/kg bolus 10 min later (180/2/180) plus half-dose TNK or to standard dose TNK monotherapy.

        Thrombolysis in Myocardial Infarction (TIMI) grade 3 epicardial flow at 60 minutes was the primary end point used in the study.

        TIMI grade 3 flow rates were similar across groups in dose-finding, with arterial patency highest for eptifibatide 180/2/180 plus half-dose TNK. The combination tended to achieve more TIMI 3 flow, arterial patency and ST-segment resolution in dose-confirmation compared to TNK monotherapy.

        But, the investigators note, combination therapy was also associated with more major haemorrhage and transfusions.
        Journal of the American College of Cardiology 2003;41:8:1251-1260. "Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send